After that, the ePV has been reported to decrease gradually after the initiation of a SGLT2 inhibitor (empagliflozin) and sustain for 12 weeks in patients with HF with reduced ejection fraction [12] and for 1 week in inpatients with T2DM and acute decompensated HF [13]. This evidence concerns the gene SLC5A2 and hydrops fetalis.